Research study Program year 2023 Source: CMS Open Payments

BI 905677 phase I first in man dose finding study

Research payments

$851,616

16 payments

Through program year 2023, $851,616 in research payments was reported against BI 905677 phase I first in man dose finding study, across 16 payments, paid by Boehringer Ingelheim Pharmaceuticals, Inc..

Paid by: Boehringer Ingelheim Pharmaceuticals, Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$38,966	2
2022	Research	$146,761	3
2021	Research	$136,493	4
2020	Research	$225,528	3
2019	Research	$303,867	4

Breakdown

Who paid Research payments · program years 2019–2023

Boehringer Ingelheim Pharmaceuticals, Inc. $851,616 16 payments

Who received the money Research payments · program years 2019–2023

Usc Norris Cancer Hospital Teaching hospital · CA $293,268 5 payments
Keck School Of Medicine Of Usc Organisation paid for research $233,467 2 payments
Memorial Sloan Kettering Cancer Center Organisation paid for research $183,896 3 payments
Memorial Sloan Kettering Cancer Center Radiology Group Organisation paid for research $95,020 1 payment
University Southern California Keck School Of Medicine Organisation paid for research $38,883 1 payment
University Of Southern California Organisation paid for research $6,096 3 payments
Sarah Cannon Research Institute Organisation paid for research $986 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

2 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.